Rivaroxaban

證據等級: L5

預測適應症: 4 個

Rivaroxaban: From Anticoagulation (VTE/AF) to Rheumatoid Arthritis

One-Sentence Summary

Rivaroxaban is a Factor Xa inhibitor used for anticoagulation (VTE prophylaxis/treatment and stroke prevention in atrial fibrillation), as referenced across the trial and literature evidence in this pack (e.g., EINSTEIN, ACT trials). The TxGNN model predicts it may be effective for Rheumatoid Arthritis, but 0 clinical trials and only 4 tangentially related publications currently support this direction, and the mechanistic rationale itself flags this as likely a comorbidity artifact rather than a true treatment signal.

Quick Overview

Item	Content
Original Indication	Not confirmed via regulatory filing (drug not marketed in Norway); evidence pack context indicates anticoagulation for VTE/AF
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	99.57%
Evidence Level	L4
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the structured drug record (MOA field is a data gap). Based on evidence within this pack, rivaroxaban is a direct Factor Xa inhibitor used for anticoagulation — it has no known anti-inflammatory or immunomodulatory activity.

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease. RA patients do carry an elevated risk of venous thromboembolism (VTE) due to chronic inflammation, and in clinical practice such patients sometimes require anticoagulant therapy — but this represents comorbidity management, not treatment of RA itself.

The evidence pack's own mechanistic assessment is explicit on this point: none of the four supporting publications demonstrate an anti-rheumatic effect of rivaroxaban. The literature instead covers VTE diagnosis/management (including in RA patients as an incidental comorbidity), thrombin generation assays in autoimmune disease, and DOAC adherence patterns. The high TxGNN score most likely reflects a learned RA–VTE comorbidity association in the knowledge graph rather than a causal RA-treatment pathway. This candidate should be interpreted with significant caution.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33141212	2020	Review	JAMA	General review of lower-extremity DVT diagnosis/treatment; not RA-specific
34175144	2021	Review	La Revue de médecine interne	Thrombin generation assay use in autoimmune disease (incl. antiphospholipid syndrome) for hypercoagulability screening; not a rivaroxaban-RA efficacy study
29621248	2018	Cohort	PLoS One	Adherence comparison of rivaroxaban vs. apixaban in atrial fibrillation; unrelated to RA
41918541	2026	Case Report	Cureus	Case of thromboembolic stroke in an 88-year-old with AF who incidentally had steroid-treated RA; RA is a background detail, not a treatment target

Norway Market Information

Currently no marketing authorization on file for rivaroxaban in Norway (0 licenses; market status: Not Marketed).

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA/label warnings, contraindications, and DDI data are flagged as a blocking data gap in this evidence pack — see Conclusion.)

Conclusion and Next Steps

Decision: Hold

Rationale: There is no clinical trial evidence and no literature directly demonstrating a therapeutic effect of rivaroxaban on rheumatoid arthritis; the drug's known Factor Xa-inhibitor mechanism has no plausible link to RA disease activity, and the supporting literature relates to VTE management in RA patients rather than RA treatment itself. Combined with an S0 decision stage and L4 evidence level, this candidate does not meet the bar to proceed.

To proceed, the following is needed:

TFDA/regulatory label data (warnings, contraindications) — currently a Blocking data gap
Confirmed mechanism of action (MOA) from DrugBank — currently a High severity data gap
Any preclinical/mechanistic study directly linking Factor Xa inhibition to RA disease pathways, if such evidence exists
Should this candidate be revisited, the other TxGNN-flagged indications for rivaroxaban in this pack (gout, HIV infection, brachydactyly-syndactyly syndrome) were also reviewed and are similarly Hold — gout and the rare skeletal disorder have essentially no supporting evidence, and HIV-related evidence concerns anticoagulant safety in HIV patients (drug-drug interactions with antiretrovirals) rather than antiviral efficacy
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.